PLX Pharma

Loading quotes...

Forecast

Buy	2
Hold	3
Sell	0

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, PLX Pharma had revenue of €7.22m and net profit of -€45.25m

(EUR)	2021	YoY
Revenue	7.22m	28,788.32%
Gross profit	2.99m	11,876.97%
Net profit	-45.25m	264.92%
EBITDA	-40.37m	239.41%

Fundamentals

Metric	Value
Market capitalization	€2.27m
Number of shares	29.14m
52-week high/low	€3.06 - €0.00807
Dividends	No
Beta	3.92
P/E ratio	-0.04
PEG ratio	0.00
P/B ratio	0.04
P/S ratio	0.31

Company profile

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.